Rhenman & Partners Asset Management Ab Alnylam Pharmaceuticals, Inc. Transaction History
Rhenman & Partners Asset Management Ab
- $840 Million
- Q1 2025
A detailed history of Rhenman & Partners Asset Management Ab transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 48,197 shares of ALNY stock, worth $15.8 Million. This represents 1.55% of its overall portfolio holdings.
Number of Shares
48,197
Previous 17,000
183.51%
Holding current value
$15.8 Million
Previous $4 Million
225.35%
% of portfolio
1.55%
Previous 0.42%
Shares
30 transactions
Others Institutions Holding ALNY
# of Institutions
724Shares Held
111MCall Options Held
978KPut Options Held
881K-
Capital World Investors Los Angeles, CA16.7MShares$5.51 Billion0.76% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$4.29 Billion0.07% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$3.14 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.15MShares$2.35 Billion0.44% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.42MShares$1.45 Billion0.79% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $40.5B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...